WebThe complement receptor 2 (Cr2) gene is exclusively expressed in B cells and follicular dendritic cells (FDC) in mice and in humans. However, mice also express an alternative … WebB cells have CR2 receptors on their surfaces, allowing the complement system to play a role in B-cell activation and maturation.It is expressed by follicular dendritic cells (FDC) and mature B cells, as well as by several types of epithelial cells. CD21 is useful in the identification of follicular dendritic cell matrix found in normal lymph ...
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell ...
WebOct 1, 2002 · Complement receptor (CR) type 2 (CR2/CD21) is normally expressed only during the immature and mature stages of B cell development. In association with CD19, CR2 plays an important role in enhancing mature B cell responses to foreign Ag. We used a murine Vlambda2 promoter/Vlambda2-4 enhancer minigene … WebJul 11, 2024 · B cell receptor (BCR) stimulation leads to the activation of downstream SRC family kinases, such as Bruton's tyrosine kinase (Btk) and spleen tyrosine kinase (Syk), which both have been reported to be crucial players in antigen-receptor signaling and B cell fate decision between MZ and FO B cells ( 26, 27 ). javascript programiz online
CR2 - ScienceDirect
WebExpression of Toll-like receptors (TLRs) in B cells provides a cell-intrinsic mechanism for innate signals regulating adaptive immune responses. In combination with other signaling pathways in B cells, including through the B-cell receptor (BCR), TLR signaling plays multiple roles in B-cell differentiation and activation. WebAug 25, 2009 · To test functional coreceptor signaling in primary B cells, the three strains of mice (WT; Cr2 −/−, ref. 17; and Cr2 Δ/Δgfp) were crossed with the B6.MD4 line, which bears a classical Ig transgene (Tg) encoding anti-hen egg lysozyme (HEL) antibody ( 36 ). WebFeb 14, 2013 · Acute leukemia OS after CR2 transplantation. Probability of survival after allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for AML (A) or ALL (B) in CR2 in adults 18-50 years of age in the United States, 2005-2007. Used with permission from the CIBMTR. javascript print image from url